The estimated Net Worth of Harry W Jr Alcorn is at least $581 mil dollars as of 15 September 2021. Dr Alcorn owns over 15,000 units of DiaMedica Therapeutics stock worth over $190,889 and over the last 6 years he sold DMAC stock worth over $0. In addition, he makes $389,925 as Sr. VP of Clinical Operations at DiaMedica Therapeutics.
Sign up
Dr D DMAC stock SEC Form 4 insiders trading
Dr has made over 5 trades of the DiaMedica Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of DMAC stock worth $57,000 on 15 September 2021.
The largest trade he's ever made was buying 20,721 units of DiaMedica Therapeutics stock on 16 August 2021 worth over $64,028. On average, Dr trades about 5,516 units every 126 days since 2018. As of 15 September 2021 he still owns at least 43,582 units of DiaMedica Therapeutics stock.
You can see the complete history of Dr Alcorn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Harry W. Alcorn Jr., Pharm.D. biography
Dr. Harry W. Alcorn Jr., Pharm.D. is the Sr. VP of Clinical Operations at DiaMedica Therapeutics.
What is the salary of Dr D?
As the Sr. VP of Clinical Operations of DiaMedica Therapeutics, the total compensation of Dr D at DiaMedica Therapeutics is $389,925. There are 2 executives at DiaMedica Therapeutics getting paid more, with Dietrich John Pauls MBA having the highest compensation of $687,579.
How old is Dr D?
Dr D is 65, he's been the Sr. VP of Clinical Operations of DiaMedica Therapeutics since . There are no older and 5 younger executives at DiaMedica Therapeutics.
What's Dr D's mailing address?
Harry's mailing address filed with the SEC is TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS, MN, 55447.
Insiders trading at DiaMedica Therapeutics
Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg y David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.
What does DiaMedica Therapeutics do?
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
What does DiaMedica Therapeutics's logo look like?
Complete history of Dr Alcorn stock trades at DiaMedica Therapeutics
DiaMedica Therapeutics executives and stock owners
DiaMedica Therapeutics executives and other stock owners filed with the SEC include:
-
Dietrich John Pauls MBA,
Pres, CEO & Director -
Rick Pauls,
President, Chief Executive Officer, Director -
Dr. Harry W. Alcorn Jr., Pharm.D.,
Sr. VP of Clinical Operations -
Scott B. Kellen C.A.,
CFO & Company Sec. -
James Parsons,
Director -
Michael Giuffre,
Independent Director -
Jerry Xiao,
Director -
Harry Alcorn,
Director -
Paul Papi,
Vice President - Business Development -
Sydney Gilman,
Vice President - Regulatory Affairs -
Scott Kellen,
Chief Financial Officer, Corporate Secretary -
Richard Pilnik,
Independent Chairman of the Board -
Dr. Edward G. Calamai Ph.D.,
Consulting Head of Manufacturing -
Tanya Lewis,
Director -
David J. Wambeke,
Chief Business Officer -
Jantrill Ab Stahlberg,
-
Dietrich John Pauls,
President and CEO -
Zhenyu Xiao,
Director -
Todd A. Verdoorn,
Chief Scientific Officer -
Koch Thomas Tom Enterprise ...,
-
Koch Thomas Tom Enterprise ...,
-
Charles Pauling Semba,
Director -
Amy L. Burroughs,
Director -
Kirsten L Gruis,
Chief Medical Officer -
Dominic R Cundari,
Chief Commercial Officer -
Julie Van Orsdel Daves,
SVP Clinical Development Oper. -
Masuoka K. Lorianne,
Chief Medical Officer -
Richard Kuntz,
Director